Description overdue on 05.10.2011

Contains Potassium   and magnesium aspartate . The ion source of magnesium and potassium. Asparkam involved in the restoration of electrolyte balance. Magnesium contributes to the penetration of potassium ions into the cell, acts as a cofactor in the 300-reaction. Potassium possesses the expressed antiarrhythmic action , Has a beneficial action on the cardiac activity. The drug reduces the severity of oxygen deprivation ( hypoxia ), Improves gastrointestinal tract, skeletal muscle contraction.

Potassium participates in nervous impulses along the fibers in synaptic transmission, muscle contraction. Metabolic disorders of potassium violates the excitability of nerves and muscles. Small dose K + expand the lumen of the coronary arteries, and high doses, in contrast, narrow lumen. Potassium has a moderate diuretic action. Magnesium is actively involved in the processes that regulate the flow and supply of energy. Mg 2+ is involved in the transport of ions, electrolyte balance, membrane permeability, stimulation of the nervous and muscular tissue. Magnesium is involved in the process of cell division, cell growth, the unit of heredity, the synthesis of RNA, the pentose phosphate leads to the structure of DNA. Mg2 + prevents and restricts excessive access catecholamine   during stressful situations. Magnesium is recognized as "physiological" BCCI.

Dosage Form:

Pills. Injection, infusion.

Indications:

Asparkam used in the complex therapy of coronary heart disease, hypokalemia and hypomagnesemia (against the background of vomiting, diarrhea and so on. N.), Heart failure, cardiac arrhythmias (with overdose of cardiac glycosides, myocardial infarction ).

Contraindications:

Expressed violations of in the work of the renal system (acute, chronic renal failure), increased concentration of of magnesium and potassium in the blood, insufficient uropoiesis, atrioventricular blockade of at sufficient level of potassium in the blood, hemolysis (damage to the structure of erythrocytes), adrenal insufficiency, dehydration, acute acidosis   blood, shock, severe myasthenia .

Side effect:

GIT: dyspepsia. CCC: conduction disturbances infarction. CNS: dizziness. When administered intravenously, the drug may result in irritation of the walls of veins at the injection site. Symptoms of of excess the content of of potassium and magnesium in the body: redness of integuments, thirst . muscular weakness .   convulsions, paresis Drop in blood pressure, fatigue, hyporeflexia Increasing the number extrasystole , Comatose state.

Mode of application:

Asparkam in tablet form take 3 times a day for 1-2 tons in a month or more. Intravenous injection of 2 times a day for 10-20 ml for 5 days. The dose can be changed depending on the individual, the degree of hypokalemia.

Special instructions:

With the rapid introduction of the drug intravenously may develop Asparkam hypermagnesemia, hyperkalemia, life-threatening arrhythmias. If there is evidence the drug can be applied to pregnant women. Heart rhythm disturbances in conjunction with atrioventricular block drug is not prescribed.

Drug Interactions:

Asparkam increases BATM and Dromotropic anti-arrhythmic drugs . Eliminates hypokalemia after taking corticosteroids, diuretics, ISS. Heparin , Cyclosporine, NSAIDs, potassium-sparing diuretics, ACE inhibitors increase the risk of hyperkalemia. Enveloping and astringent drugs reduce asparkama absorption in the gastrointestinal tract. General anesthetics reinforce a depressing effect on the CNS. When joint reception with decamethonium, atrakuroniem, suksvmetoniem, succinyl chloride is amplified neuromuscular blockade. In combination with insulin   and Dextrose   (as part of the polarizing mixture) normalizes heart rhythm ectopic arrhythmias, myocardial infarction, cardiac glycoside overdose. Improves portability cardiac glycosides, pharmaceutically compatible with them.